Related Experiment Video
Updated: Jun 5, 2025

08:02
In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells
Published on: September 23, 2021
2.5K
The Lymphatic Vascular System in Extracellular Vesicle-Mediated Tumor Progression
Pragati Lodha1,2,3, Alperen Acari1,2,3, Jochen Rieck1,2
1European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, 68167 Mannheim, Germany.
Cancers
|December 17, 2024
Summary
Extracellular vesicles (EVs) from tumors travel via the lymphatic system, influencing immune escape and metastasis. Understanding this pathway is key to developing new cancer therapies.
Area of Science:
- Oncology
- Cell Biology
- Vascular Biology
Background:
- Tumor growth involves complex cell interactions.
- Extracellular vesicles (EVs) mediate molecular communication between cancer cells and host cells.
- EVs can promote tumor immune escape and metastasis by altering recipient cell functions.
Purpose of the Study:
- To highlight the critical role of the lymphatic vascular system in the distribution and progression-promoting functions of tumor cell-derived EVs.
- To emphasize the tumor-draining lymph node as a key site for EV-mediated effects.
- To underscore the need for mechanistic understanding of EV transport and interaction within the lymphatic system for therapeutic development.
Main Methods:
- Review and synthesis of recent studies on extracellular vesicle (EV) transport.
- Focus on the lymphatic vascular system's role in EV distribution from solid tumors.
- Analysis of EV interactions within tumor-draining lymph nodes and beyond.
Main Results:
- The lymphatic vascular system is the primary route for the regional and systemic distribution of tumor-derived EVs.
- Tumor-draining lymph nodes are crucial sites where EVs exert their effects.
- EVs contribute to the formation of pre-metastatic niches, facilitating tumor spread.
Conclusions:
- The lymphatic system is essential for the spread of tumor-derived EVs and subsequent tumor progression.
- Targeting EV transport or interaction within the lymphatic system offers potential therapeutic strategies.
- Further research into the mechanisms of EV lymphatic uptake and function is crucial for novel cancer treatments.
Related Concept Videos
The Tumor Microenvironment
6.5K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.5K
Intralumenal Vesicles and Multivesicular Bodies
3.4K
Intraluminal vesicles (ILVs) are small vesicles 50-80 nm in diameter formed during the maturation of early endosomes. A specialized endosome containing numerous ILVs is called a multivesicular body (MVB). ILVs contain internalized molecules such as antigens, nucleic acids, proteins, and metabolites. Some of these molecules are released from the MVBs inside exosomes and are transported to other cells. Other MVBs contain molecules that are retained in the ILVs and are later degraded within the...
3.4K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K

